tbuckley/cabot-search huggingface dataset:
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial
Authors: Carlos M. Grilo, Valentina Ivezaj, Cenk Tek, Sydney Yurkow, Ashley A. Wiedemann, Ralitza Gueorguieva
Journal: American Journal of Psychiatry (2024)

Binge-eating disorder (BED) is a prevalent, costly public health problem associated with serious functional impairments and heightened rates of psychiatric and medical comorbidities. Few evidence-based treatments are currently available for BED. We tested the effectiveness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT+LDX, for BED comorbid with obesity. Randomized controlled trial was conducted March 2019 to September 2023 at a single site. N=141 patients with BED (83.7% women, mean age 43.6, mean BMI 38.6 kg/m2) were randomized to one of three 12-week treatments: CBT (N=47), LDX (N=47), or CBT+LDX (N=47); 87.2% completed independent posttreatment assessments. Mixed models revealed binge-eating frequency decreased significantly in all treatments, with CBT+LDX having the largest reduction and significantly outperforming CBT and LDX, which did not differ. Intention-to-treat binge-eating remission rates differed significantly between treatments, with CBT+LDX having the highest remission rate (70.2%) followed by CBT (44.7%) and LDX (40.4%). Mixed models revealed percent weight loss increased significantly throughout treatment with LDX and CBT+LDX but remained unchanged in CBT. LDX and CBT+LDX had significantly greater percent weight loss than CBT starting after one month and through posttreatment. Intention-to-treat rates of attaining ≥5% weight loss differed across treatments, with LDX having the highest (53.2%), followed by CBT+LDX (42.6%) and CBT (4.3%). Analyses revealed significant reductions in eating-disorder psychopathology; CBT+LDX had largest reductions and significantly outperformed CBT and LDX. CBT, LDX, and CBT+LDX showed significant improvements in BED, with a consistent pattern of the combined CBT+LDX being superior to the two individual treatments, which differed little.
Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial
Authors: George Kypriotakis, Paul M. Cinciripini, Charles E. Green, David Lawrence, Robert M. Anthenelli, Jennifer A. Minnix, Diane Beneventi, Chad Morris, Maher Karam-Hage, Janice A. Blalock
Journal: American Journal of Psychiatry (2024)

The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD). This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling. The primary safety outcome was occurrence of one or more moderate to severe neuropsychiatric adverse events. Efficacy was assessed as biochemically verified continuous abstinence during weeks 9-12. Among all 6,653 participants, the risk of neuropsychiatric adverse events did not differ by medication within the past-MDD, current-MDD, or nonpsychiatric cohorts. The MDD cohorts had higher risk difference (p<0.001) for neuropsychiatric adverse events compared with the nonpsychiatric cohort (past-MDD cohort, risk difference=-0.03, 95% CI=-0.05, -0.02; current-MDD cohort, risk difference=-0.02, 95% CI=-0.05, 0.00). Within the past-MDD cohort, the odds ratios compared with placebo were 3.0 (95% CI=2.0, 4.5) for varenicline, 2.1 (95% CI=1.6, 2.7) for bupropion, and 2.1 (95% CI=1.4, 3.2) for NRT. Within the current-MDD cohort, varenicline differed from placebo (odds ratio=2.67, 95% CI=1.2, 6.15) and NRT (odds ratio=2.93, 95% CI=1.2, 7.2). All medications were generally safe in both MDD cohorts. NRT and bupropion were not more effective than placebo for those with current MDD. Varenicline plus counseling may be the best treatment for individuals with past or current MDD, given its greater efficacy, similar risk of adverse events, and, for those with current depression, reductions in anxiety and depression while trying to quit smoking.
Cancer situation in China: an analysis based on the global epidemiological data released in 2024
Authors: Xiayao Diao, Chao Guo, Yukai Jin, Bowen Li, Xuehan Gao, Xin Du, Zhenchong Chen, Minju Jo, Yi Zeng, Chao Ding, Wenwu Liu, Jianrong Guo, Shanqing Li, Haibo Qiu
Journal: Cancer Communications (2024)

Abstract Background Cancer remains a major cause of mortality and a significant economic burden in China. Exploring the disparities in cancer patterns and control strategies between China and developed countries may offer valuable insights for policy formulation and enhance cancer management efforts. This study examined the incidence, mortality, and disability‐adjusted life year (DALY) burden of cancer in China, and compared these metrics with those observed in the United States (US) and the United Kingdom (UK). Methods Data on cancer incidence, mortality, and DALYs for China, the US, and the UK were sourced from the GLOBOCAN 2022 online database and the Global Burden of Disease 2021 study (GBD 2021). We utilized Joinpoint regression models to analyze trends in cancer incidence and mortality across these countries, calculating annual percent changes (APCs) and determining the optimal joinpoints. Results In 2022, China recorded around 4,824,703 new cancer cases and 2,574,176 cancer‐related deaths, contributing to 71,037,170 DALYs. China exhibited a lower cancer incidence rate compared to the US and the UK. Although cancer‐related mortality in China is slightly lower than that in the UK, it is significantly higher than that in the US. Additionally, China experienced significantly higher DALY rates compared to both the US and UK. The cancer landscape in China was also undergoing significant changes, with a rapid rise in the incidence and burden of lung, colorectal, breast, cervical, and prostate cancers. Meanwhile, the incidence and burden of stomach cancer continued to decline. Although the incidence of liver and esophageal cancers was decreasing, the burden of liver cancer was increasing, while the burden of esophageal cancer remained largely unchanged. Conclusions The cancer profile of China is shifting from that of a developing country to one more typical of a developed country. The ongoing population aging and the rise in unhealthy lifestyles are expected to further escalate the cancer burden in China. Consequently, it is crucial for Chinese authorities to revise the national cancer control program, drawing on successful strategies from developed countries, while also accounting for the regional diversity in cancer types across China.
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis.
Authors: Alberto Zanetto, Elena Campello, Cristiana Bulato, Ruth Willems, Joke Konings, Mark Roest, Sabrina Gavasso, Giorgia Nuozzi, Serena Toffanin, Patrizia Burra, Francesco Paolo Russo, Marco Senzolo, Bas de Laat, Paolo Simioni
Journal: Journal of Hepatology (2024)

The clinical utility of thrombomodulin-modified thrombin generation (TM-TG) in cirrhosis is uncertain. We conducted a prospective study to evaluate the prognostic value of TM-TG in cirrhosis.
Lipoprotein (a) in the Full Spectrum of MASLD; Evidence from Histologically and Genetically Characterized Cohorts
Authors: Hong Fan, Matina Kouvari, Geltrude Mingrone, Jacob George, Georgios Papatheodoridis, Laura Valenzuela-Vallejo, Zhenqiu Liu, Xingdong Chen, Tiejun Zhang, Christos S Mantzoros
Journal: Clinical Gastroenterology and Hepatology (2024)
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer
Authors: Chenyang Li, Chujun Cai, Chendong Wang, Xiaoping Chen, Bixiang Zhang, Zhao Huang
Journal: Clinical and Molecular Hepatology (2024)

The trillions of commensal microorganisms living in the gut lumen profoundly influence the physiology and pathophysiology of the liver though a unique gut-liver axis.Disruptions in the gut microbial communities, arising from environmental and genetic factors, can lead to altered microbial metabolism, impaired intestinal barrier and translocation of microbial components to the liver.These alterations collaboratively contribute to the pathogenesis of liver disease, and their continuous impact throughout the disease course plays a critical role in hepatocarcinogenesis. Persistent inflammatory responses, metabolic rearrangements and suppressed immunosurveillance induced by microbial products underlie the pro-carcinogenic mechanisms of gut microbiota.Meanwhile, intrahepatic microbiota derived from the gut also emerges as a novel player in the development and progression of liver cancer.In this review, we first discuss the causes of gut dysbiosis in liver disease, and then specify the pivotal role of gut microbiota in the malignant progression from chronic liver diseases to hepatobiliary cancers.We also delve into the cellular and molecular interactions between microbes and liver cancer microenvironment, aiming to decipher the underlying mechanism for the malignant transition processes.At last, we summarize the current progress in the clinical implications of gut microbiota for liver cancer, shedding light on microbiota-based strategies for liver cancer prevention, diagnosis and therapy.
High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
Authors: Veronica González‐Calle, Paula Rodriguez‐Otero, Maria J. Calasanz, Manuela Guijarro, Joaquin Martínez‐López, Laura Rosiñol, Miguel T. Hernández, Ana I. Teruel, Mercedes Gironella, Albert Oriol, Javier de la Rubia, Ana P. González‐Rodríguez, Joan Bargay, Felipe de Arriba, Luis Palomera, Marta‐Sonia González‐Pérez, Anna Sureda, Enrique Ocio, Juan J. Lahuerta, Joan Bladé, Jesus F. San Miguel, Maria V. Mateos, Norma C. Gutiérrez
Journal: HemaSphere (2024)

This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM-PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH on CD38 purified plasma cells. The frequency of genetic alterations detected were as follows: del(17p) in 8%, t(4;14) in 12%, t(14;16) in 3%, +1q in 43%, and del(1p) in 8%. The median follow-up was 61 months, and the median progression-free survival (PFS) and overall survival (OS) were 44 months and not reached, respectively. Consistent with previous reports, the presence of t(4;14) was associated with shorter PFS and OS. In our series, the presence of t(14;16) did not impact survival, maybe due to limitations in sample size. Del(17p) was linked to poor prognosis using a cut-off level of ≥20% positive cells, without any impact of higher cut-off in prognosis, except for patients with clonal fraction ≥80% who had a dismal outcome. Cosegregation of cytogenetic abnormalities patients worsened the prognosis in t(4;14) patients but not in patients with del(17p), which retained its adverse prognosis even as a solitary abnormality. Gain(1q) was associated with significantly shorter PFS and OS, while del(1p) affected PFS but not OS. Nevertheless, when co-segregation was eliminated, the detrimental effect of +1q or del(1p) was no longer observed. In conclusion, this study confirms the prognostic significance of high-risk cytogenetic abnormalities in MM and highlights the importance of considering co-occurrence for accurate prognosis assessment.
Novel carbon dots with dual Modulatory effects on the bone marrow and spleen as a potential therapeutic candidate for treating spinal cord injury
Authors: Junjin Li, Hongda Wang, Yuanquan Li, Chunzhen Wang, Haiwen Feng, Yilin Pang, Jie Ren, Chuanhao Li, Erke Gao, Dejing Zhang, Dunxu Hu, Pengtian Zhao, Han Ding, Baoyou Fan, Tao Zhang, Xiaomeng Song, Zhijian Wei, Guangzhi Ning, Yong-Qiang Li, Shiqing Feng
Journal: Bioactive Materials (2024)
Integrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening
Authors: Yu-Hong Wang, Ting-Ting Liu, Yan-Ping Guo, Shuo-Ji Zhu, Zi-Ming Liao, Jia-Mei Song, Xi-Ming Zhu, Jia-Liang Liang, Moussa Ide Nasser, Nan-Bo Liu, De-Hua Chang, Ping Zhu, Bin Yao
Journal: Bioactive Materials (2024)
Do Sepsis Alerts Help?
Authors: Derek C. Angus
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Electronic Sepsis Screening Among Patients Admitted to Hospital Wards
Authors: Yaseen M. Arabi, Abdulmohsen Alsaawi, Mohammed Alzahrani, Ali M. Al Khathaami, Raed H. AlHazme, Abdullah Al Mutrafy, Ali Al Qarni, Ramesh Kumar Vishwakarma, Rasha Al Anazi, Eman Al Qasim, Sheryl Ann Abdukahil, Fawaz K. Al-Rabeah, Huda Al Ghamdi, Abdulaleem Alatassi, Hasan M. Al-Dorzi, Fahad Al-Hameed, Razan Babakr, Abdulaziz A. Alghamdi, Salih Bin Salih, Ahmad Alharbi, Mufareh Edah AlKatheri, Hani Mustafa, Saad Al-Qahtani, Shaher Al Qahtani, Nahar Alselaim, Nabiha Tashkandi, Ali H. Alyami, Zeyad Alyousef, Omar AlDibasi, Abdul Hadi Al-Qahtani, Abdulaziz Aldawood, Angela Caswell, Nouf Al Ayadhi, Hadeel Al Rehaili, Ahmed Al Arfaj, Hatami Al Mubarak, Turki Alwasaidi, Saleh Zahrani, Yousef Alalawi, Abdulrahman Alhadab, Tariq Nasser, Tagwa Omer, Sameera M. Al Johani, Abdulaziz Alajlan, Musharaf Sadat, Mohammed Alzunitan, Saad Al Mohrij, Ebtisam Al Ghamdi, Haifa Al Shammari, Sarah Al Zighaibi, Fady Al Harbi, Mohammed Al Kanhel, Saad Al Nofaie, Mohamed Al Moammary, Soud Rasheed, Tariq Debasi, Khadega Abuelgasim, Faisal Thekair, Saleh Qasim, Saeed Obbed, Jamila Al Onazi, Majid Alshamrani, Abdul Rahman Jazieh, Ashwaq Al Olayan, Mohamed Al Harbi, Georges Nammour, Joan Jones, Amal Matroud, Jacqueline Hendricks, Judelyn Jambalos, Pauline Maake, Florbela Maria Ribeiro, Arlene Panadero, Mohammed Al Qarni, Wasil Jastaniah, Arwa Yamani, Hassan AlMarhabi, Omer Abuskout, Basem Banat, Eman Matar, Elizabeth Moodi, Jayshree Naidoo, Hala Ghamdi, Mayadah Habshi, Adnan Munshi, Abdullah Bin Hamdan, Talal Swilem, Jamal Chalabi, Michael Lorentziadis, Mohammed Shahin, Jamielah Yaakob, Johanna Greyvenstein, Sami  Musalam Aliyyen, Christa Myumi Sian, Ahmad Salahaldeen, Shantal Pienaar, Sukaina Al Tuwal, Waleed K. Al-Arfaj, Abdulaziz Al Qasem, Ahmed Al Shouabi, Abdulatif Alaraj, Gaber Madram, Wafa Nasser, Raed Al Almoodi, Hanan AlSomali, Clara Masala, Fatimah Talaqof, Eman Al Mostafa, Mastura Sharry, Maryam Al Mulhim, Amar Alhasani, Ahmad Qureshi, Muhammad Anis, Ibrahim Jaber, Noha Omaish, Azurahazri Abd Rahim, Basmah Alharbi, Naif AlMughamisi
Journal: JAMA (2024)

Sepsis screening is recommended among hospitalized patients but is supported by limited evidence of effectiveness.
Role of gut microbes in acute lung injury/acute respiratory distress syndrome
Authors: Zixuan Ren, Zhihuan Zheng, Xiujing Feng
Journal: Gut Microbes (2024)

Acute lung injury (ALI) is an acute, diffuse inflammatory lung condition triggered by factors of severe infections, trauma, shock, burns, ischemia-reperfusion, and mechanical ventilation. It is primarily characterized by refractory hypoxemia and respiratory distress. The more severe form, acute respiratory distress syndrome (ARDS), can progress to multi-organ failure and has a high mortality rate. Despite extensive research, the exact pathogenesis of ALI and ARDS remains complex and not fully understood. Recent advancements in studying the gut microecology of patients have revealed the critical role that gut microbes play in ALI/ARDS onset and progression. While the exact mechanisms are still under investigation, evidence increasingly points to the influence of gut microbes and their metabolites on ALI/ARDS. This review aims to summarize the role of gut microbes and their metabolites in ALI/ARDS caused by various triggers. Moreover, it explores potential mechanisms and discusses how gut microbe-targeting interventions might offer new clinical strategies for the treatment of ALI/ARDS.
Modular functionalization of cellular nanodiscs enables targeted delivery of chemotherapeutics into tumors
Authors: Ilkoo Noh, Zhongyuan Guo, Rui Wang, Audrey T Zhu, Nishta Krishnan, Animesh Mohapatra, Weiwei Gao, Ronnie H Fang, Liangfang Zhang
Journal: Journal of Controlled Release (2024)
Heyndrickxia coagulans spore-based nanoparticle generator for improved oral insulin delivery and hypoglycemic therapy
Authors: Jinying Liang, Mengxin Bai, Yarong Bi, Xiangjie Jian, Siyan Wang, Shang Jiang, Ying Zhao, Weiwei Ma, Yaping Yin, Wenli Zhang
Journal: Journal of Controlled Release (2024)
Principles for introducing new genes and species for conservation
Authors: Michael K. Schwartz, Summer L. Dunn, William A.C. Gendron, Jennifer E. Helm, W. Sebastian Kamau, Melanie Mark-Shadbolt, Axel Moehrenschlager, Kent H. Redford, Gregory Russell, Ronald L. Sandler, Courtney A. Schultz, Blake Wiedenheft, Amanda S. Emmel, Jedediah F. Brodie
Journal: Trends in Ecology & Evolution (2024)
Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data
Authors: Hyuna Sung, Rebecca L Siegel, Mathieu Laversanne, Chenxi Jiang, Eileen Morgan, Mariam Zahwe, Yin Cao, Freddie Bray, Ahmedin Jemal
Journal: The Lancet Oncology (2024)

Previous studies have shown that colorectal cancer incidence is increasing among younger adults (aged <50 years) in multiple high-income western countries in contrast with stabilising or decreasing trends in incidence in older adults (aged ≥50 years). This study aimed to investigate contemporary colorectal cancer incidence trends in younger adults versus older adults.
Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis
Authors: Raul G Nogueira, Tudor G Jovin, Xinfeng Liu, Wei Hu, Lucianne C M Langezaal, Chuanhui Li, Qiliang Dai, Chunrong Tao, Francisco J A Mont'Alverne, Xunming Ji, Rui Liu, Rui Li, Diederik W J Dippel, Chuanjie Wu, Wusheng Zhu, Pengfei Xu, Wim H van Zwam, Longfei Wu, Chao Zhang, Patrik Michel, Jian Chen, Li Wang, Volker Puetz, Wenbo Zhao, Tianlong Liu, Heinrich J Audebert, Zhongjun Chen, Octavio M Pontes-Neto, Tingyu Yi, Timothy P Moran, Mohamed F Doheim, Wouter J Schonewille
Journal: The Lancet (2024)
Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study
Authors: Narmeen Mallah, Jacobo Pardo-Seco, Olaia Pérez-Martínez, Carmen Durán-Parrondo, Federico Martinón-Torres, Narmeen Mallah, Jacobo Pardo-Seco, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro-Sánchez, Ana Dacosta-Urbieta, Irene Rivero-Calle, Angela Manzanares-Casteleiro, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres
Journal: The Lancet Infectious Diseases (2024)
Single-use gastroscopes: evolution, revolution, or involution?
Authors: Enrique Rodriguez de Santiago, Heiko Pohl
Journal: Endoscopy (2024)

Evolution signifies gradual improvement or steady adaptation. Revolution, by contrast, marks a radical shift, transforming the norm. Involution is a reversion inward, often with regressive outcomes. The emergence of single-use gastroscopes leads us to question whether this is truly a revolutionary innovation or a potential step backward.
Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study
Authors: Eleni A Argyriadi, Ingo G Steffen, Christiane Chen-Santel, Andrej Lissat, Andishe Attarbaschi, Jean-Pierre Bourquin, Guenter Henze, Arend von Stackelberg
Journal: Leukemia (2024)

Relapsed Acute Lymphoblastic Leukemia (ALL) is among the most common causes of cancer-associated deaths in children. However, little is known about the implications of deviations from ALL treatment protocols on survival rates. The present study elucidates the various characteristics of treatment deviations in children with relapsed ALL included in the ALL-REZ BFM 2002 (i.e., Relapse Berlin-Frankfurt- Münster) trial and determines their prognostic relevance for relapse and death rates. Among 687 patients, 100 were identified with treatment deviations, further classified, and examined by occurrence time, cause and type. Protocol deviation was considered a time-dependent variable and its impact on Disease Free Survival (DFS) and Overall Survival (OS) was examined using the time-dependent model Mantel Byar. Five years after the relapse diagnosis, deviations were significantly related to both inferior DFS (38%) and OS (57%) rates compared to protocol conformed treatment (DFS = 61%; OS = 70%, P < 0.001). Based on multivariate analyses, protocol deviation proved to be an independent adverse prognostic factor of DFS. Moreover, deviations triggered by chemotherapy-induced toxicity were associated with a higher relapse rate compared to deviations due to insufficient response. Therefore, to avoid impairment of results by deviations, future clinical trials, and treatment strategies should focus on less toxic treatments and stricter protocol compliance.
Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Authors: Haruko Shima, Chikako Tono, Akihiko Tanizawa, Masaki Ito, Akihiro Watanabe, Yuki Yuza, Kazuko Hamamoto, Hideki Muramatsu, Masahiko Okada, Shoji Saito, Hiroaki Goto, Masaru Imamura, Akiko M Saito, Souichi Adachi, Eiichi Ishii, Hiroyuki Shimada
Journal: Leukemia (2024)
Self-improving generative foundation model for synthetic medical image generation and clinical applications
Authors: Jinzhuo Wang, Kai Wang, Yunfang Yu, Yuxing Lu, Wenchao Xiao, Zhuo Sun, Fei Liu, Zixing Zou, Yuanxu Gao, Lei Yang, Hong-Yu Zhou, Hanpei Miao, Wenting Zhao, Lisha Huang, Lingchao Zeng, Rui Guo, Ieng Chong, Boyu Deng, Linling Cheng, Xiaoniao Chen, Jing Luo, Meng-Hua Zhu, Daniel Baptista-Hon, Olivia Monteiro, Ming Li, Yu Ke, Jiahui Li, Simiao Zeng, Taihua Guan, Jin Zeng, Kanmin Xue, Eric Oermann, Huiyan Luo, Yun Yin, Kang Zhang, Jia Qu
Journal: Nature Medicine (2024)
Dengue virus importation risks in Africa: a modelling study
Authors: Jenicca Poongavanan, José Lourenço, Joseph L-H Tsui, Vittoria Colizza, Yajna Ramphal, Cheryl Baxter, Moritz U G Kraemer, Marcel Dunaiski, Tulio de Oliveira, Houriiyah Tegally
Journal: The Lancet Planetary Health (2024)